BIOMAT Database Logo BIOMAT Database Logo

Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. 1999

Y Nawata, and K Kurasawa, and K Takabayashi, and S Miike, and N Watanabe, and M Hiraguri, and Y Kita, and M Kawai, and Y Saito, and I Iwamoto
Department of Internal Medicine, Chiba University School of Medicine, Japan.

OBJECTIVE To determine the characteristics of corticosteroid resistant interstitial pneumonitis (IP) in dermatomyositis (DM) and polymyositis (PM), and to evaluate the effect of cyclosporine on corticosteroid resistant IP in DM/PM. METHODS We analyzed retrospectively the incidence, clinical features, and corticosteroid responses of IP in 111 patients with DM (56) or PM (55). All patients with DM/PM were treated with prednisolone, and corticosteroid resistant IP was defined as a progression of IP despite administration of 1 mg/kg/day prednisolone for more than 4 weeks. We also evaluated the effect of cyclosporine on corticosteroid resistant IP in patients with DM/PM. RESULTS IP occurred in 24 of 56 DM and 12 of 55 PM patients. We then classified IP in DM/PM according to serum CPK levels at the onset of IP; IP associated with high CPK levels (type I) (19) and IP associated with normal CPK levels (type II) (17). Only 2 of 19 (11%) type I IP were resistant to prednisolone therapy, while 14 of 17 (82%) type II IP were resistant to prednisolone therapy. Thus, patients with type II IP showed poorer prognosis than those with type I IP (one year survival rate: type I 89% vs type II 31%). Cyclosporine was effective in all 5 cases with corticosteroid resistant IP in DM/PM (one year survival rate 80%). CONCLUSIONS (1) Corticosteroid resistant IP develops mostly in patients with DM/PM without CPK elevation at the onset of IP (type II IP), and (2) cyclosporine is effective for the corticosteroid resistant IP in DM/PM and significantly prolongs survival of patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D003882 Dermatomyositis A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6) Polymyositis-Dermatomyositis,Dermatomyositis, Adult Type,Dermatomyositis, Childhood Type,Dermatopolymyositis,Juvenile Dermatomyositis,Juvenile Myositis,Adult Type Dermatomyositis,Childhood Type Dermatomyositis,Dermatomyositis, Juvenile,Myositis, Juvenile,Polymyositis Dermatomyositis
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001327 Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. Autoimmune Disease,Disease, Autoimmune,Diseases, Autoimmune

Related Publications

Y Nawata, and K Kurasawa, and K Takabayashi, and S Miike, and N Watanabe, and M Hiraguri, and Y Kita, and M Kawai, and Y Saito, and I Iwamoto
Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis.
October 1987, The Journal of rheumatology,
Y Nawata, and K Kurasawa, and K Takabayashi, and S Miike, and N Watanabe, and M Hiraguri, and Y Kita, and M Kawai, and Y Saito, and I Iwamoto
Cyclosporine treatment for interstitial pneumonitis associated with dermatomyositis/polymyositis.
January 1998, Internal medicine (Tokyo, Japan),
Y Nawata, and K Kurasawa, and K Takabayashi, and S Miike, and N Watanabe, and M Hiraguri, and Y Kita, and M Kawai, and Y Saito, and I Iwamoto
Interstitial pneumonitis in association with polymyositis and dermatomyositis.
April 1974, Chest,
Y Nawata, and K Kurasawa, and K Takabayashi, and S Miike, and N Watanabe, and M Hiraguri, and Y Kita, and M Kawai, and Y Saito, and I Iwamoto
Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis?
January 1997, Scandinavian journal of rheumatology,
Y Nawata, and K Kurasawa, and K Takabayashi, and S Miike, and N Watanabe, and M Hiraguri, and Y Kita, and M Kawai, and Y Saito, and I Iwamoto
Cyclosporine treatment for dermatomyositis/polymyositis.
January 1993, Cutis,
Y Nawata, and K Kurasawa, and K Takabayashi, and S Miike, and N Watanabe, and M Hiraguri, and Y Kita, and M Kawai, and Y Saito, and I Iwamoto
[Prognosis of interstitial pneumonitis (IP) in polymyositis (PM)/dermatomyositis (DM)].
February 1994, Ryumachi. [Rheumatism],
Y Nawata, and K Kurasawa, and K Takabayashi, and S Miike, and N Watanabe, and M Hiraguri, and Y Kita, and M Kawai, and Y Saito, and I Iwamoto
Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis.
September 1999, Internal medicine (Tokyo, Japan),
Y Nawata, and K Kurasawa, and K Takabayashi, and S Miike, and N Watanabe, and M Hiraguri, and Y Kita, and M Kawai, and Y Saito, and I Iwamoto
[Successful therapy with cyclosporine in a case with interstitial pneumonitis associated with polymyositis].
April 1996, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology,
Y Nawata, and K Kurasawa, and K Takabayashi, and S Miike, and N Watanabe, and M Hiraguri, and Y Kita, and M Kawai, and Y Saito, and I Iwamoto
Interstitial pneumonitis in dermatomyositis.
April 1956, Journal of the American Medical Association,
Y Nawata, and K Kurasawa, and K Takabayashi, and S Miike, and N Watanabe, and M Hiraguri, and Y Kita, and M Kawai, and Y Saito, and I Iwamoto
Treatment of corticosteroid-resistant polymyositis with methotrexate.
January 1971, Lancet (London, England),
Copied contents to your clipboard!